Literature DB >> 2908713

Effect of calcium entry blockers on blood pressure and vasoconstrictor responses to alpha-1 adrenoceptor stimulation in conscious spontaneously hypertensive rats.

M J Thoolen1, C R Miller, A T Chiu, P B Timmermans.   

Abstract

In order to investigate whether vascular alpha-1 adrenoceptor antagonism plays a role in the antihypertensive effect of verapamil, tiapamil, and nifedipine, we studied their potencies to inhibit K(+)-induced 45Ca2+ influx in rat isolated aorta and [3H]prazosin binding in rat brain membranes in vitro as well as their antihypertensive effect and functional alpha-1 adrenoceptor blockade in conscious spontaneously hypertensive rats (SHR) in vivo. Tiapamil proved 70 times less potent than verapamil in inhibiting calcium influx, but was equipotent in displacing [3H]prazosin. Nifedipine proved 10 times more potent than verapamil as calcium channel blocker but displayed negligible affinity for alpha-1 adrenoceptors in vitro. In conscious SHR, the three calcium channel blockers dose-dependently reduced mean arterial pressure after oral administration. Only at maximal anti-hypertensive doses, the increases in diastolic pressure to intravenous injection of the selective alpha-1 adrenoceptor agonist cirazoline were temporarily suppressed by nifedipine, verapamil, and tiapamil. No relationship existed between the relative potencies as calcium channel blocker and affinities for alpha-1 adrenoceptor binding sites in vitro with functional vascular alpha-1 adrenoceptor blockade in vivo. The data do not support the hypothesis that vascular alpha-1 adrenoceptor blockade plays a significant role in the anti-hypertensive effect of verapamil and related calcium channel blockers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2908713     DOI: 10.1007/BF02209079

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  23 in total

1.  Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states.

Authors:  D A Greenberg; D C Prichard; S H Snyder
Journal:  Life Sci       Date:  1976-07-01       Impact factor: 5.037

2.  Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors.

Authors:  D C U'Prichard; D A Greenberg; S H Snyder
Journal:  Mol Pharmacol       Date:  1977-05       Impact factor: 4.436

3.  Selectivity of some alpha adrenoceptor agonists for peripheral alpha-1 and alpha-2 adrenoceptors in the normotensive rat.

Authors:  J C van Meel; A de Jonge; P B Timmermans; P A van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

4.  The interaction of calcium antagonists (slow channel blockers) with myocardial alpha adrenoceptors.

Authors:  W G Nayler; J E Thompson; B Jarrott
Journal:  J Mol Cell Cardiol       Date:  1982-03       Impact factor: 5.000

5.  Organic and inorganic calcium antagonists reduce vasoconstriction in vivo mediated by postsynaptic alpha 2-adrenoceptors.

Authors:  J C Van Meel; A de Jonge; H O Kalkman; B Wilffert; P B Timmermans; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-07       Impact factor: 3.000

6.  Phenoxybenzamine-induced inhibition of cirazoline pressor responses in pithed rats pretreated with organic or inorganic calcium entry blocking drugs.

Authors:  J Bou; R Massingham
Journal:  Eur J Pharmacol       Date:  1984-07-20       Impact factor: 4.432

7.  Antihypertensive activity and interaction with alpha-adrenoceptors of tibalosine ([1-(2, 3-dihydro-5-benzo-(b)-thienyl)-2-(4-phenyl-butylamino)-1-propanol], CP 804 S) in rat and cat preparations.

Authors:  J Q Qian; M J Mathy; M J Thoolen; P B Timmermans; P A van Zwieten
Journal:  Arch Int Pharmacodyn Ther       Date:  1983-12

Review 8.  Antihypertensive and arterial anticalcinotic effects of calcium antagonists.

Authors:  A Fleckenstein; M Frey; G Fleckenstein-Grün
Journal:  Am J Cardiol       Date:  1986-02-26       Impact factor: 2.778

9.  Calcium-channel blockers for combined angina pectoris and systemic hypertension.

Authors:  W H Frishman; S Charlap; B Kimmel; J Goldberger; G Phillippides; N Klein
Journal:  Am J Cardiol       Date:  1986-02-26       Impact factor: 2.778

10.  Differential inhibition of vascular smooth muscle responses to alpha 1- and alpha 2-adrenoceptor agonists by diltiazem and verapamil.

Authors:  I Cavero; N Shepperson; F Lefèvre-Borg; S Z Langer
Journal:  Circ Res       Date:  1983-02       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.